XML 48 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1

Subsequent event	3 Months Ended
	Mar. 31, 2017
Subsequent event
Subsequent event	14 Subsequent event On April 20, 2017, the Company announced that it will not pursue the renewal of the Glybera® (alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017. The Company will continue to supply product to Chiesi to treat any patients that are approved for treatment prior to October 25, 2017, and will be responsible for terminating the Phase IV post-approval study. According to the termination agreement executed in April 2017, the Company will be required to make installment payments to Chiesi totaling $2.2 million through January 2019. Additionally, the Company may owe up to an additional $1.8 million depending on the number of patients treated with Glybera prior to its withdrawal, if any. Any such payments related to additional patients treated will be payable no earlier than April 1, 2019, in accordance with a schedule to be agreed upon by the parties.

X

- References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration